Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin.
Reduced effectiveness of the most common antiplatelet drug, acetylsalicylic acid (ASA, aspirin), in diabetes mellitus has been associated with a lowered platelet sensitivity to ASA and related to glycemic control in diabetic patients. Our objectives were (a) to monitor the chemical background of how chronic hyperglycemia affects platelet response to ASA in diabetes and (b) to study a chemical competition between the amount of bound acetyl residues and the extent of protein glycation in blood platelets. Using whole-blood impedance aggregometry and platelet function analyzer (PFA-100) we observed a reduced platelet response to ASA in diabetic patients (14% vs. 79% for PFA-100 collagen-epinephrine occlusion time) and an association between the index of glycemic control and platelet refractoriness to ASA (r(S) = -0.378). Impaired platelet response to ASA was related to enhanced platelet protein glycation (3.6+/-0.4 in diabetes vs. 2.3+/-0.4 micromol fructosamine/microg protein in control) and reduced incorporation of acetyl residue into proteins of platelets from diabetic patients (47.4+/-2.0 in control vs. 33.1+/-0.7 micromol acetyl/microg protein in diabetic subjects). Incubation of blood platelets with increasing concentrations of glucose and ASA under in vitro conditions led to excessive modification in protein amino groups: glucose and ASA competed with each other in the course of nonenzymatic modifications, glycosylation, or acetylation, and their contributions to the occupancy of protein amino groups (R2 = 0.22 for glucose, R2 = 0.43 for ASA) were dependent upon the concentrations of glucose and ASA. Overall the effects of high glucose and high ASA on the overall occupancy of protein free amino groups are not additive. While at higher concentrations ASA overcomes the effects of hyperglycemia and retards glycation, high glucose makes acetylation less efficient, and therefore the resultant chemical modification becomes greatly reduced. In conclusion, diminished susceptibility of various platelet proteins and receptors on blood platelet membranes to acetylation and high ambient glucose might underlie the apparently differentiated sensitivity of blood platelets to ASA and determine platelet "insensitivity to aspirin" in diabetic patients.
Watala
Cezary
C
Department of Hemostasis and Hemostatic Disorders, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland. cwatala@csk.am.lodz.pl
Pluta
Justyna
J
Golanski
Jacek
J
Rozalski
Marcin
M
Czyz
Malgorzata
M
Trojanowski
Zygmunt
Z
Drzewoski
Józef
J
D000107:Acetylation / Q000187:drug effects; D000328:Adult; D001241:Aspirin / Q000008:administration & dosage* / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D003094:Collagen / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004837:Epinephrine / Q000378:metabolism; D005260:Female; D005947:Glucose / Q000378:metabolism; D006031:Glycosylation / Q000187:drug effects; D006801:Humans; D006943:Hyperglycemia; D008297:Male; D008565:Membrane Proteins / Q000097:blood / Q000737:chemistry / Q000187:drug effects; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology
D008565:Membrane Proteins; D010975:Platelet Aggregation Inhibitors; D003094:Collagen; D005947:Glucose; D001241:Aspirin; D004837:Epinephrine
Diabetes. 1992 Mar;41(3):261-6
1551486
J Am Coll Cardiol. 2003 Mar 19;41(6):961-5
12651041
Thromb Res. 1989 Dec 15;56(6):763-6
2633404
Biochem Pharmacol. 2001 Nov 15;62(10):1399-408
11709200
Can J Physiol Pharmacol. 1994 Mar;72(3):295-303
8069776
Invest Ophthalmol Vis Sci. 1989 Jun;30(6):1120-6
2525117
Thromb Haemost. 2002 Nov;88(5):711-5
12428082
J Immunol Methods. 1994 Jan 3;167(1-2):121-7
7905897
Anal Biochem. 1985 Oct;150(1):76-85
3843705
Thromb Res. 2003 Mar 15;109(5-6):299-306
12818254
Am J Cardiol. 2001 Aug 1;88(3):230-5
11472699
Br Med J. 1976 Apr 24;1(6016):994-6
1083757
Am J Physiol Heart Circ Physiol. 2001 Apr;280(4):H1480-9
11247757
Blood. 1986 Oct;68(4):886-91
3092890
J Pharm Pharmacol. 1997 Mar;49(3):273-6
9231344
Diabetes Care. 2004 May;27(5):1245-6
15111568
Diabetes Care. 1997 May;20(5):832-5
9135951
Biochem J. 1982 Apr 1;203(1):313-21
7103944
Thromb Haemost. 1992 Nov 10;68(5):577-82
1455404
Semin Thromb Hemost. 1998;24(2):195-202
9579642
Stroke. 1992 Jun;23(6):851-4
1595104
Acta Physiol Pharmacol Latinoam. 1986;36(3):313-6
3577806
Indian J Exp Biol. 1998 Jul;36(7):651-7
9782780
Semin Thromb Hemost. 1991 Oct;17(4):433-8
1803514
Biochem Biophys Res Commun. 1994 Mar 15;199(2):683-6
8135810
Platelets. 1999;10(1):52-60
16801071
Ophthalmic Res. 1993;25(6):349-54
8309673
Thromb Res. 2002 Sep 15;107(6):319-23
12565718
Biochem Pharmacol. 1993 Mar 24;45(6):1343-9
8385461
J Thromb Haemost. 2003 Aug;1(8):1710-3
12911581
Diabetes Care. 2003 Dec;26(12):3264-72
14633812
Exp Eye Res. 1999 Jul;69(1):109-15
10375455
Eur J Haematol. 1993 May;50(5):264-8
8319788
J Thromb Thrombolysis. 2002 Feb;13(1):49-56
11994560
Thromb Res. 2004;113(2):101-13
15115665
BMJ. 2003 Jan 11;326(7380):82-3
12521973
J Lab Clin Med. 1986 Oct;108(4):286-93
3760670
J Mol Med (Berl). 2002 Dec;80(12):796-801
12483465
Ann Thorac Surg. 1994 Apr;57(4):981-6
8166553
Diabetes Care. 2004 Jan;27 Suppl 1:S72-3
14693931
Diabetes Care. 2003 Jul;26(7):2181-8
12832332
Nat Struct Biol. 1995 Aug;2(8):637-43
7552725
Circulation. 1999 Jan 19;99(2):224-9
9892587